EMEA-002582-PIP01-19-M01
Key facts
| Active substance |
Remibrutinib
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0170/2022
|
| PIP number |
EMEA-002582-PIP01-19-M01
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic spontaneous urticaria
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|